Author:
Fernandes Ricardo R.A.,Barros Bruno M.,da Costa Milene R.,Magliano Carlos A.S.,Tura Bernardo R.,Morais Quenia Cristina D.,Santos Marisa
Subject
Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)
Reference15 articles.
1. Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna;Brault;Lancet Reg Health West Pac,2022
2. Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study;Cerqueira-Silva;Lancet Reg Health Am,2022
3. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials;Lai;Viruses,2022
4. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19;Hammond;N Engl J Med,2022
5. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients;Najjar-Debbiny;Clin Infect Dis,2023